transcription factor Dp family member 3Genealiases: CT30 · DP4 · HCA661
Q-omics provides the consensus-scored TFDP3 profile across patient tissues and cancer cell-line models. TFDP3 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TFDP3 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, TFDP3 RNA expression shows 10,009 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, THCA, and TGCT as cancer lineages where TFDP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TFDP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TFDP3 survival associations across molecular data types. TFDP3 RNA expression shows survival associations in the most cancer types (16), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TFDP3 RNA expression–survival associations across cancer types. High TFDP3 expression shows unfavorable associations in KIRC, KICH, SCLC and PAAD, but favorable associations in OV and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TFDP3 RNA expression.
This table summarizes TFDP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TFDP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TFDP3 shows lower tumor expression in THCA and KIRC and higher tumor expression in LIHC, HNSC, UCEC and PRAD. The THCA box plot shows higher TFDP3 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .002).
This table shows molecular features associated with TFDP3 in patient tissues and cancer cell lines. In patient samples, TFDP3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TFDP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
